{"id":"peg-somatropin","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Carpal tunnel syndrome"},{"rate":null,"effect":"Fluid retention"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Somatropin is a recombinant human growth hormone (hGH) that mimics endogenous GH by binding to growth hormone receptors on target tissues. Pegylation (attachment of polyethylene glycol) extends the drug's half-life, allowing for less frequent dosing compared to non-pegylated somatropin. This enables sustained activation of GH signaling pathways that regulate protein synthesis, lipolysis, and linear growth.","oneSentence":"PEG-somatropin is a pegylated recombinant human growth hormone that binds to growth hormone receptors to promote growth, metabolism, and body composition changes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:35:46.707Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Growth hormone deficiency in children"},{"name":"Growth hormone deficiency in adults"}]},"trialDetails":[{"nctId":"NCT07260500","phase":"PHASE2","title":"A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-11-11","conditions":"Short Stature Children Born Small for Gestational Age (SGA)","enrollment":72},{"nctId":"NCT06037473","phase":"","title":"The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg","status":"RECRUITING","sponsor":"Beijing Children's Hospital","startDate":"2023-08-01","conditions":"Growth Hormone Treatment, Growth Disorders","enrollment":2600},{"nctId":"NCT03255694","phase":"PHASE2","title":"A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2017-05-12","conditions":"Dwarfism","enrollment":360},{"nctId":"NCT06797505","phase":"PHASE1","title":"A Bioequivalence Study of Two Different PEG-rhGH Preparations","status":"COMPLETED","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-02-10","conditions":"Pediatric Growth Hormone Deficiency (PGHD)","enrollment":87},{"nctId":"NCT02375620","phase":"PHASE2","title":"Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2015-04-23","conditions":"Short Stature Children Born Small for Gestational Age (SGA)","enrollment":96},{"nctId":"NCT06135168","phase":"PHASE1","title":"A Clinical Trail to Compare Pharmacokinetics of Two PEG-rhGH Injections With Different Preparations","status":"COMPLETED","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2023-10-31","conditions":"Pediatric Growth Hormone Deficiency (PGHD)","enrollment":60},{"nctId":"NCT06135155","phase":"PHASE1","title":"A Clinical Trial to Compare Pharmacokinetics of Two Different PEG-rhGH Preparations","status":"COMPLETED","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2023-11-06","conditions":"Pediatric Growth Hormone Deficiency (PGHD)","enrollment":48},{"nctId":"NCT06385145","phase":"PHASE1","title":"A Bioavailability Study of Two Different PEG-rhGH Preparations.","status":"COMPLETED","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2024-05-08","conditions":"Pediatric Growth Hormone Deficiency (PGHD)","enrollment":16},{"nctId":"NCT06863363","phase":"PHASE4","title":"PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"","conditions":"Non-diabetic Obesity","enrollment":212},{"nctId":"NCT06840691","phase":"PHASE1","title":"A Bioequivalence Study of Two Different Processes of PEG-rhGH Preparations","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-05","conditions":"Pediatric Growth Hormone Deficiency (PGHD)","enrollment":87},{"nctId":"NCT06768411","phase":"NA","title":"The Dosage Exploration Study of PEG-rhGH for Treating Short Stature in Prepubertal and Pubertal Children","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2025-01-15","conditions":"Short Stature","enrollment":240},{"nctId":"NCT06722079","phase":"","title":"A Real-world Study of Long-acting Growth Hormone Injection for Turner Syndrome","status":"COMPLETED","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2022-11-08","conditions":"Turner Syndrome","enrollment":743},{"nctId":"NCT06331026","phase":"PHASE1","title":"A Bioequivalence Study of Two Different PEG-rhGH Preparations.","status":"COMPLETED","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2024-04-09","conditions":"Pediatric Growth Hormone Deficiency (PGHD)","enrollment":87},{"nctId":"NCT06110910","phase":"","title":"Long-term Efficacy and Safety Evaluation of Growth Hormone in Children in China(CGLS)","status":"RECRUITING","sponsor":"Xiaoping Luo","startDate":"2023-03-01","conditions":"Childhood Short Stature","enrollment":10000},{"nctId":"NCT06448195","phase":"PHASE4","title":"Effects of Growth Hormone Therapy on Metabolic Function in Fatty Liver Post-Pituitary Adenoma Surgery","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2023-01-01","conditions":"Growth Hormone Treatment","enrollment":40},{"nctId":"NCT06007417","phase":"PHASE3","title":"A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2023-12-01","conditions":"GHD","enrollment":162},{"nctId":"NCT06024967","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone Deficiency","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2023-12-01","conditions":"GHD","enrollment":180},{"nctId":"NCT05144035","phase":"PHASE4","title":"A Real World Study of the Effect of Early PEG-rhGH Therapy on Cognitive Development of SGA Infants","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-04-06","conditions":"Small for Gestational Age Infant, Growth Hormone Treatment, Cognitive Developmental Disorder","enrollment":138},{"nctId":"NCT04588844","phase":"NA","title":"Effect of Growth Hormone Injection on the IVF/ICSI Outcome of Patients With Poor Ovarian Reserve.","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2020-12-01","conditions":"Poor Ovarian Reserve","enrollment":200},{"nctId":"NCT03189160","phase":"PHASE2","title":"A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2016-03","conditions":"Turner Syndrome","enrollment":180},{"nctId":"NCT03290235","phase":"PHASE4","title":"Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2017-03-01","conditions":"Growth Retardation","enrollment":1500},{"nctId":"NCT03249480","phase":"PHASE4","title":"Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2015-01","conditions":"Growth Hormone Deficiency","enrollment":900},{"nctId":"NCT01342146","phase":"PHASE2","title":"Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children","status":"COMPLETED","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2006-05","conditions":"Growth Hormone Deficiency","enrollment":101},{"nctId":"NCT01495468","phase":"PHASE3","title":"Phase III Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children","status":"COMPLETED","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2007-03","conditions":"Growth Hormone Deficiency","enrollment":343},{"nctId":"NCT03221088","phase":"PHASE2","title":"A Study of PEG-somatropin in the Treatment of Children With Idiopathic Short Stature","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2015-06","conditions":"Dwarfism","enrollment":360},{"nctId":"NCT02380235","phase":"PHASE4","title":"Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I)","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2014-12","conditions":"Growth Hormone Deficiency","enrollment":600},{"nctId":"NCT02976675","phase":"PHASE4","title":"Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2015-01","conditions":"Growth Hormone Deficiency","enrollment":600},{"nctId":"NCT02908958","phase":"PHASE4","title":"Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2014-11","conditions":"Growth Hormone Deficiency","enrollment":900},{"nctId":"NCT03104010","phase":"PHASE2","title":"A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2017-04","conditions":"Adult Growth Hormone Deficiency","enrollment":180},{"nctId":"NCT02314676","phase":"PHASE4","title":"Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2014-11","conditions":"Dwarfism, Pituitary","enrollment":900},{"nctId":"NCT01613573","phase":"PHASE1","title":"Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children","status":"COMPLETED","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2010-03","conditions":"Growth Hormone Deficiency","enrollment":12},{"nctId":"NCT01010425","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)","status":"COMPLETED","sponsor":"Ascendis Pharma A/S","startDate":"2009-11","conditions":"Healthy","enrollment":44},{"nctId":"NCT00778518","phase":"PHASE2","title":"Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).","status":"COMPLETED","sponsor":"Ambrx, Inc.","startDate":"2008-07","conditions":"Growth Hormone Deficiency","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Jintrolong®","Polyethylene Glycol Recombinant Human Somatropin Injection","recombinant human growth hormone","peglyated growth hormone","PEG-GH"],"phase":"marketed","status":"active","brandName":"PEG-somatropin","genericName":"PEG-somatropin","companyName":"Changchun GeneScience Pharmaceutical Co., Ltd.","companyId":"changchun-genescience-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PEG-somatropin is a pegylated (polyethylene glycol-conjugated) recombinant human growth hormone that binds to growth hormone receptors to promote growth, metabolism, and body composition changes. Used for Growth hormone deficiency in children, Growth hormone deficiency in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}